The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Lintuzumab-Ac225 and CLAG-M for R/R AML
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study (NCT03441048) investigating the combination of lintuzumab-Ac225 and the CLAG-M standard chemotherapy regimen in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). The results indicate that the combination is safe and relatively well tolerated, with no unexpected adverse events observed. The overall response rate (ORR) was 73%, of which 67% of participants achieved a complete response (CR). 70% of participants showed measurable residual disease (MRD) negativity as measured by flow cytometry. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
